Joe Marion

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

Christopher Butler, Richard Hobbs, Oghenekome Gbinigie et al. · The Lancet · 2022 · 406 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +7

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

Sahil Khanna, Maha Assi, Christine Lee et al. · Drugs · 2022 · 269 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +15

Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial

Christopher Butler, Richard Hobbs, Oghenekome Gbinigie et al. · SSRN Electronic Journal · 2022 · 52 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +17

Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease

Oghenekome Gbinigie, Emma Ogburn, Julie Allen et al. · BMJ Open · 2023 · 26 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis

Sabrina Paganoni, Christina Fournier, Eric A. Macklin et al. · JAMA Network Open · 2025 · 18 citations · Full text

Medicine, Neurology, Pharmacology +15